pcsk9 in 2

PCSK9-IN-2 is a newly developed small molecule that effectively inhibits the protein-protein interaction (PPI) between PCSK9 and LDLR. It has been found to have a potent inhibitory activity with an IC50 value of 7.57 μM.

PCSK9 modulator-2 (Compound 1) is a potent PCSK9 modulator (EC 50 = 202 nM) with potential applications in hyperlipidemia research. Proprotein convertase subtilisin kexin type 9 (PCSK9) is a recently validated therapeutic target for lowering low-density lipoprotein cholesterol (LDL-C) [1].

SPC4061, a potent PCSK9 inhibitor and an antisense nucleotide, specifically targets the lock-in nucleic acid (LNA) of PCSK9. This action is relevant for researching hypercholesterolemia and associated diseases [1] [2].

Recaticimab (SHR-1209) is a humanized monoclonal antibody targeting PCSK9 to enhance its degradation. By binding to PCSK9, Recaticimab elevates low-density lipoprotein (LDL) receptor presence on hepatocyte surfaces, consequently lowering plasma LDL levels and aiding in blood lipid reduction. This positions Recaticimab as a promising therapeutic for hypercholesterolemia [1] [2].

Pep 2-8 ammonium salt is Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor. Potent inhibitor of PCSK9 binding to LDL receptor (IC50 = 0.8 μM). Restores LDL uptake in HepG2 cells treated with PCSK9.